Table 1.

Survey of epigenetic drug trials in cancer and immunotherapy trials in sarcoma

NCT numberAgentOther agentInclusionPhaseStartEndEnrollment
EZH2 inhibitor trials
NCT02082977GSK2816126Diffuse large B-cell lymphomaI20142017100
NCT01897571E7438Diffuse large B-cell lymphomaI/II20132015154
NCT02395601CPI-1205B-cell lymphomaI2015201641
Bromodomain inhibitor trials
NCT02259114OTX015Advanced solid tumorsI2014201698
NCT02296476OTX015Glioblastoma multiformeI/II2014201651
NCT02303782OTX015AzacitidineAcute myeloid leukemiaI/II2015201688
NCT01949883CPI-0610Progressive lymphomaI2013201533
NCT02157636CPI-0610Multiple myelomaI2014201536
NCT02158858CPI-0610LeukemiasI2014201536
NCT02419417BSM-986158PaclitaxelAdvanced solid tumorsI/II20152020185
NCT01587703GSK525762NUT midline carcinomaI2012201890
NCT02391480ABBV-075Advanced cancerI2015201778
NCT02308761TEN-010AML and myelodysplastic syndromeI2014201768
NCT01987362TEN-010Advanced solid tumorsI2013201666
NCT02369029BAY1238097NeoplasmsI20152017140
Immunotherapy trials in sarcoma
NCT01643278IpilimumabDasatinibGIST, advanced sarcomaI2012201539
NCT02210104IpilimumabCyclophosphamide, CD4 T cellsNY-ESO–expressing, advanced sarcomaI2015201812
NCT02406781PembrolizumabCyclophosphamide (metronomic)Advanced sarcomaII20152017163
NCT02304458Nivolumab(±) IpilimumabRecurrent childhood sarcomasI/II20152016204
NCT02428192NivolumabAdvanced uterine LMSII2015201637
NCT02301039PembrolizumabAdvanced sarcomasII2015201880
NCT01241162DecitabineDendritic cell (lysate pulsed)Relapsed pediatric sarcoma, neuroblastomaI2010201515
NCT01522820DEC-205/NY-ESO-1 fusionSirolimusAdvanced, NY-ESO-1–expressingI2012201618
NCT02387125LV305 (viral NY-ESO-1 expression)NY-ESO-1 vaccineSynovial sarcoma, myxoid liposarcomaIB2015201733
NCT01291420Dendritic cells (transfected)Recurrent sarcoma (limited disease)I/II2011201410
NCT01343043NY-ESO-1 T cellsSynovial sarcomaI2011201610
NCT02319824NY-ESO-1 T cellsRadiation therapyNY-ESO-1–expressing sarcomasI2015201612
NCT02059850NY-ESO-1 T cellsCyclophosphamideSynovial sarcoma, myxoid liposarcomaI2014201612
NCT02387125CMB305Metastatic, NY-ESO-1–expressingI2015201733
NCT02457650NY-ESO-1 T cellsCyclophosphamide; fludarabineNY-ESO-1–expressing cancersI2015201936
NCT02122861ID-LV305Advanced, NY-ESO-1–expressingI2014201642
NCT01883518Dendritic cell vaccine (cancer-testis antigens)SarcomaI/II2013201548

Abbreviations: AML, acute myeloid leukemia; GIST, gastrointestinal stromal tumors; LMS, leiomyosarcoma.